-
58m 38s
-
1h 27m
-
1h 3m 31s
-
1h 12m 7s
-
36m 57s
-
51m 18s
Presentations
- Key Overview of Recently Completed and On-Going Trials: Translations to Clinical Practice
- The Reversal Debate
Radcliffe Cardiology was proud to host New Horizons in Cardiomyopathy 2025 (NHC), specially focused on cardiac amyloidosis and cardiomyopathy diagnosis and treatment.
Day 1 focused on hypertrophic cardiomyopathy (HCM), with a detailed exploration of HCM and an emphasis on emerging therapies and management strategies. Day 2 focused on amyloidosis, providing a comprehensive update on the diagnosis and treatment of cardiac amyloidosis, along with insights into the latest research and clinical practices.
The course directors, Prof Rodney Falk (Brigham and Women’s Hospital, US), Prof Perry Elliott (University College London, UK), and Prof Marianna Fontana (University College London, UK), led a distinguished group of faculty members who are renowned experts in the field of cardiac amyloidosis and HCM.
NHC was designed to educate healthcare professionals on the evolving management practices in cardiac amyloidosis and cardiomyopathy in an informal and engaging learning environment featuring thought-provoking presentations, cases and practical masterclasses.
*Please note, the live version of New Horizons in Cardiomyopathy was accredited. The on-demand version is not.
Learning Objectives
- Increase the awareness of at-risk patients
- Improve understanding of screening procedures
- Provide guidance on the use of imaging for diagnosis
- Improve awareness on current and emerging treatment
- Provide guidance on initiating treatment and managing comorbidities
Target Audience
- Cardiologists (device implanters, heart failure)
- Imaging Specialists
- Electrophysiologists
- Primary Care
- Haematologists
- Cardiac Nurse Practitioners
More from this programme
Part 1
Day 1: Session 1 – The Cardiomyopathy Mindset
In this opening session of NHC, presentations cover the basics of cardiomyopathy diagnosis, including when to suspect it and overview of the diagnostic pathway. The faculty present on clinical indicators for suspicion and discuss case studies.
Part 2
Day 1: Session 2 – The Diagnostic Pathway
Session 2 focuses on the diagnostic pathway. Faculty discuss assessing the ventricular function in the diagnosis of cardiomyopathy, diagnostic tools and phenotyping.
| 1 session | |
| Watch now |
Part 3
Day 1: Session 3 – The Management of Cardiomyopathy
This session highlights the critical role of risk stratification and prognostic assessment in the management of hypertrophic cardiomyopathy. The discussion also delves into the management strategies tailored to hypertrophic cardiomyopathy patients through a case study approach.
Part 4
Day 2: Session 1 – Amyloidosis Specific Diagnosis
This session covers amyloidosis diagnosis, featuring a case study on key clinical clues. It explores scintigraphy challenges and CMR imaging's role in cardiac amyloidosis.
Part 5
Day 2: Session 2 – Implementation in Practice
The faculty dive into a complex case, examining the challenges of both diagnosing and managing a patient, providing valuable insights into navigating such multifaceted scenarios.
Part 6
Day 2: Session 3 – Phenotyping Management Strategies
This session focuses on phenotyping management strategies for amyloidosis. The faculty discuss collaborating with haematologists to address cardiac complexities and complications that arise during chemotherapy.
Part 7
Day 2: Session 4 – The Treatment Horizon
In the final session of the event, faculty provide an overview of recently completed and on-going trials.
| 1 session | |
| Watch now |
Faculty Biographies
Rodney Falk
Associate Professor
Dr Rodney Falk is a prominent figure in the field of cardiology, holding the esteemed position of director for the Cardiac Amyloidosis Program and serving as a specialist in cardiovascular medicine at Brigham and Women's Hospital (BWH). In addition, he is an associate professor of medicine at Harvard Medical School, reflecting his involvement in both clinical practice and academia.
Dr Falk's academic journey commenced with the acquisition of his medical degree from the University of Birmingham Medical School in the United Kingdom. His rigorous training encompasses a trio of residencies: one in internal medicine at Brook General Hospital, another in internal medicine at City Hospital, and a cardiology program at King's College Hospital, all situated in London, UK. Complementing his extensive background, he furthered his expertise with a cardiology fellowship at Harvard School of Public Health, emphasizing his dedication to continued learning and…
Arnt Kristen
Arnt Kristen practices in Heidelberg, Germany. His top areas of expertise are Primary Amyloidosis, Transthyretin Amyloidosis, Cardiac Amyloidosis, Heart Transplant, and Tissue Biopsy.
Margot Davis
Director, University of British Columbia (UBC) Cardiology-Oncology Program, Vancouver General Hospital, Vancouver, Canada
Dr Margot Davis is a cardiologist at Vancouver General Hospital and St. Paul's Hospital, as well as the director of the UBC Cardiology-Oncology Program and a clinical assistant professor at the University of British Columbia (UBC).
Dr Davis is a key panel member of the CCS Cardio-Oncology Guidelines, a secondary panel member of the CCS Heart Failure Guidelines, and co-chair of the CCS/CHFS Position Statement on Cardiac Amyloidosis. She is vice president of the Canadian Cardiac Oncology Network and a member of the Executive Committee of the Board of Directors of the Canadian Heart Failure Society. Her research focuses on cardiac amyloidosis, severe heart failure, and cancer therapy-related heart disease prevention, diagnosis, and management.
Julian Gillmore
Julian Gillmore gained his medical degree at University of London. He trained in nephrology and undertook MD and PhD degrees in the field of amyloidosis. His research interests include pathogenesis, diagnosis and treatment of amyloidosis.